Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Outlook Therapeutics's total assets was $26.18M at Jun 30, 2026. For fiscal 2025 it was $18.58M, down 35.5% from the year before. Over ten years it grew -6.1% a year on average. The highest annual figure on record is $35.01M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $18.58M | -35.5% |
| FY2024 | Sep 30, 2024 | $28.82M | -10.8% |
| FY2023 | Sep 30, 2023 | $32.30M | +13.2% |
| FY2022 | Sep 30, 2022 | $28.53M | +25.1% |
| FY2021 | Sep 30, 2021 | $22.81M | +15.6% |
| FY2020 | Sep 30, 2020 | $19.73M | +15.2% |
| FY2019 | Sep 30, 2019 | $17.13M | -23.1% |
| FY2018 | Sep 30, 2018 | $22.28M | +7.5% |
| FY2017 | Sep 30, 2017 | $20.73M | -18.4% |
| FY2016 | Sep 30, 2016 | $25.41M | -27.4% |
| FY2015 | Sep 30, 2015 | $35.01M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $26.18M | +16.9% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $21.89M | +14.8% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $18.24M | +7.2% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $18.58M | -35.5% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $22.39M | -52.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $19.08M | -67.7% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $17.01M | -21.6% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $28.82M | -10.8% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $47.09M | +5.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $59.03M | +9.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $21.68M | -65.4% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $32.30M | +13.2% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $44.45M | +15.2% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $54.02M | -31.3% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $62.69M | +174.8% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $28.53M | -13.2% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $38.59M | +208.3% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $78.68M | +298.7% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $22.81M | -24.6% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $32.88M | +149.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $12.52M | +20.1% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $19.73M | +15.2% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $30.24M | -8.9% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $13.17M | -23.3% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $10.42M | -44.3% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $17.13M | -23.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $33.21M | -2.6% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $17.17M | -38.2% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $18.71M | -42.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $22.28M | +7.5% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $34.09M | +99.0% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $27.79M | +59.1% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $32.28M | +57.9% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $20.73M | -18.4% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $17.13M | -48.1% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $17.46M | -29.7% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $20.45M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $25.41M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $32.99M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $24.83M | – |
See a number that looks wrong?